Exclusive Interview with our Chair Mark McCord-Amasis from Seattle Genetics
"The Pharma sector is entering a very exciting time and flection point. The promise of cell and gene therapies (C>) is creating a whole host of new biotech focused on delivering these novel medicines to patients. Artificial intelligence and machine learning approaches are raising expectations that R&D may not only be more innovative, but also more time/cost-effective. The challenge for asset management will be to…"